Sun Pharma Ratings Affirmed: CRISIL AAA/Stable, ICRA AAA/Stable for NCDs and Facilities
Sun Pharma's credit ratings have been affirmed by CRISIL and ICRA. CRISIL assigned 'AAA/Stable' to proposed NCDs and reaffirmed 'AAA/Stable' and 'A1+' for existing facilities. ICRA assigned '[ICRA]AAA (Stable)' to proposed NCDs and reaffirmed '[ICRA]A1+' for other facilities. These ratings consider the company's strong financial profile and the proposed Organon acquisition.
Credit ratings directly influence a company's ability to raise debt, its borrowing costs, and investor confidence. High ratings like 'AAA' suggest strong creditworthiness, which is crucial for large-scale operations and significant future investments like the proposed Organon acquisition.
The affirmation and assignment of high credit ratings (AAA/Stable and A1+) by major rating agencies like CRISIL and ICRA indicate a strong financial health and positive outlook for the company, despite acknowledging potential risks.
Sun Pharmaceutical Industries Limited has received updated credit ratings from CRISIL Ratings Limited and ICRA Limited. CRISIL has assigned a 'Crisil AAA/Stable' rating to the proposed Non-Convertible Debenture (NCD) programme and reaffirmed 'Crisil AAA/Stable' for long-term ratings and 'Crisil A1+' for short-term ratings on existing facilities and commercial paper. ICRA has assigned '[ICRA]AAA (Stable)' to proposed NCDs and reaffirmed '[ICRA]A1+' for commercial paper and long/short-term fund-based/non-fund-based limits.
These ratings consider Sun Pharma's strong business and financial profile, including its leadership in the domestic formulations segment, significant presence in the US and other regulated markets, and a robust specialty products portfolio. The ratings also factor in the proposed acquisition of Organon & Co. For Sun Pharma Laboratories Limited (SPLL), a wholly-owned subsidiary, ICRA has reaffirmed its '[ICRA]A1+' rating for short-term facilities aggregating ₹150 crore.
The detailed rationales highlight Sun Pharma's healthy operating performance, with Q1 FY2027 revenue increasing by approximately 10% year-on-year to ₹15,300 crore, driven by strong growth in India formulations and global innovative medicines. However, US formulations sales declined by 10% due to weakness in the generics business. Operating profit rose by 2.7% to ₹4,418 crore, with a moderated operating margin of 29%.
CRISIL expects revenue to grow at a high single-digit rate annually over the medium term, supported by the scale-up of the innovative medicines portfolio. Operating margins are projected to remain healthy at 26-27%. The report also notes potential regulatory risks and susceptibility to intense competition and US policy uncertainties as key monitorable factors.
The proposed acquisition of Organon & Co. for $11.75 billion is expected to significantly strengthen Sun Pharma's global scale and diversify its business profile. Upon completion, the combined entity is projected to rank among the top 25 global pharmaceutical companies with pro-forma revenue of around $12.4 billion. The transaction is largely debt-funded, which is expected to temporarily increase leverage, with net debt to EBITDA estimated at 1.5-2.0 times in fiscal 2028.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.